AstraZeneca's outperforming fourth-quarter results show it is indeed back on the growth track, thanks to its cancer drugs—and once again, China.

Playing catch-up in orphan drugs, China will cut tax rates for some therapies by more than 80%.

Takeda pulls an FDA filing for Ninlaro and is ordered to pay $155 million in a Shire patent case; a cancer startup gets Chinese investors' attention.

A former deputy director of the old China FDA has been handed to the prosecutors over suspected duty-related crimes.

The FDA has found another Chinese drugmaker disregarding FDA standards with the production of its OTC products.

The Sandoz manufacturing network will be further 'optimized' as Novartis turns Sandoz into an autonomous unit in the next 18 months.

Takeda's dengue vaccine clears phase 3; Pfizer launches China's first pay-for-performance deal in oncology; Aslan cuts 30% of its workforce.

Biologics CDMO Samsung BioLogics has kept up its frantic growth even as it deals with legal issues tied to its joint venture with Biogen.